Search Medical Condition
Please enter condition
Please choose location from dropdown

Forest Hills, New York Clinical Trials

A listing of Forest Hills, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (3503) clinical trials

Safety Study of IgAN LN MN & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

This is a Phase 2, multicenter study of OMS721 in subjects with the following diseases: IgA Nephropathy (IgAN), Lupus Nephritis, Membranous Nephropathy (MN), or C3 Glomerulopathy, including Dense Deposit Disease. Three cohorts will be enrolled. Cohort 1 will be subjects with corticosteroid dependent IgAN, LN, MN, or C3 Glomerulopathy. Cohort ...

Phase

2.48 miles

Learn More »

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

This is a limited prospective collection of whole blood samples from pregnant women with a diagnosis of preterm preeclampsia and/or fetal growth restriction in addition to samples from a control group to aid in the development of a Next Generation Sequencing (NGS)-based assay to detect molecular markers associated with preterm ...

Phase N/A

2.48 miles

Learn More »

Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients

Aggressive care in Intensive Care Units (ICUs) has been shown to impair the quality of life of patients with advanced cancer and to increase the risk of Posttraumatic Stress Disorder (PTSD) among the family and friends who serve as informal caregivers. Although ICU stays are established indicators of low quality ...

Phase N/A

2.48 miles

Learn More »

Pediatric Residency Training On Tobacco

The American Academy of Pediatrics and other leading health agencies call upon pediatricians to address environmental tobacco smoke (ETS), prevent smoking onset in youths, and encourage cessation of tobacco use by adolescents and their parents. Systematic intervention on tobacco by pediatricians would protect infants and young children from the harmful ...

Phase

2.48 miles

Learn More »

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

This study is to evaluate the effectiveness of a single-dose intervertebral disc injection of SI-6603 in subjects with lumbar disc herniation (LDH)

Phase

2.48 miles

Learn More »

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 240 study centers, globally. The investigational drug (sparsentan) is a dual-acting angiotensin receptor blocker and endothelin receptor antagonist. The ...

Phase

2.48 miles

Learn More »

Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?

This is a multicenter prospective study of low-risk nulliparous women who will be recruited if they are having an ultrasound at 36 weeks of estimated gestational age or greater. As part of the study, women will have umbilical and middle cerebral artery Doppler studies and the CPR will be calculated ...

Phase N/A

2.48 miles

Learn More »

Chronic Hypertension and Pregnancy (CHAP) Project

During pregnancy, chronic hypertension (CHTN) is the most common major medical disorder encountered, occurring in 2-6%. The substantial negative effect of CHTN on pregnancy includes a consistent 3- to 5-fold increase in superimposed preeclampsia and adverse perinatal outcomes (fetal or neonatal death, preterm birth -PTB, poor fetal growth and placental ...

Phase

2.48 miles

Learn More »

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

HCC patients with chronic HBV (+) (HBsAg(+) and IgM anti-HBc (-)), and Child-Pugh A status will be randomized to either the study arm (YIV-906 plus sorafenib) or control arm (placebo plus sorafenib). Patients will be stratified according to metastatic status (extrahepatic/vascular invasion vs. none), and their ECOG performance status (0 ...

Phase

2.48 miles

Learn More »

Prospective Randomized Study of Accelerated Radiation Therapy (PRART)

Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).

Phase

2.48 miles

Learn More »